Bioceres Crop Solutions Corp.
Description
Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops. The Crop Protection segment develops, produces, and markets Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, and baits. The Crop Nutrition segment develops, produces, commercializes, and sells inoculants, bio-inductors, and biological and microgranulated fertilizers. It also offers HB4, a drought tolerant seed technology program. The company operates in Argentina, Brazil, North America, Europe, the Middle East, South America, the United States, and internationally. Bioceres Crop Solutions Corp. was founded in 2001 and is headquartered in Rosario, Argentina.
About
CEO
Dr. Federico Trucco Ph.D.
Employees
0
Instrument type
Common Stock
Sector
Basic Materials
Industry
Agricultural Inputs
MIC code
XNGS
Address
Ocampo 210 bis, Rosario, 2000, Argentina
×
![Enlarged Chart]()
Oscillators
No data available
Summary
No data available
Moving Averages
No data available
Earnings
| Date | Estimate EPS | Actual EPS | Difference | % Surprise |
|---|---|---|---|---|
| Feb 12, 2025 | — | — | — | — |
| Nov 12, 2024 | -0.01 | -0.09 | -0.08 | 800.00% |
| Sep 10, 2024 | 0.24 | -0.03 | -0.27 | -112.50% |
| May 14, 2024 | 0.17 | 0.14 | -0.03 | -17.65% |
| Feb 9, 2024 | 0.09 | 0.02 | -0.07 | -77.78% |
Earnings estimate
|
Next Quarter
(Mar 2025)
|
Current Year
(Jun 2025)
|
Next Year
(Jun 2026)
|
||
|---|---|---|---|---|
| Number of analysts | — | 3 | 3 | 2 |
| Average estimate | — | -0.03 | 0.28 | 0.54 |
| Low estimate | — | -0.08 | 0.16 | 0.46 |
| High estimate | — | 0.02 | 0.43 | 0.61 |
| Last year EPS | — | 0.14 | 0.05 | 0.28 |
[stock_revenue_estimate]
Growth estimates
Current qtr
9,515.380%
Next qtr. (Mar 2025)
-121.580%
Current year (Jun 2025)
457.770%
Next year (Jun 2026)
91.070%
Next 5 years (per annum)
—
Past 5 years (per annum)
—
Income statement
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fiscal date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Total reported revenue | 464.83M | 419.45M | 328.46M | 206.70M | 172.35M |
| Cost of revenue | 282.40M | 240.59M | 203.68M | 116.81M | 93.41M |
| Gross profit | 182.43M | 178.85M | 124.78M | 89.89M | 78.94M |
| Operating expense | |||||
| Research & development | 17.18M | 15.35M | 6.95M | 5.62M | 4.20M |
| Selling general and admin | 94.27M | 85.54M | 57.36M | 36.24M | 28.92M |
| Other operating expenses | 5.09M | 982,780 | 4.78M | 863,671 | 813,525 |
| Operating income | 41.52M | 54.31M | 40.32M | 37.95M | 38.17M |
| Non operating interest income | |||||
| Income | — | — | — | — | — |
| Expense | 24.12M | 21.23M | 14.95M | 18.92M | 19.40M |
| Other income expense | -4.62M | -11.42M | -8.33M | -6.18M | -20.06M |
| Pretax income | 10.04M | 19.11M | 14.06M | 10.53M | 6.44M |
| Tax provision | 3.78M | -1.07M | 17.97M | 14.35M | 2.21M |
| Net income | 6.26M | 20.17M | -3.91M | -3.82M | 4.24M |
| Basic EPS | 0.05 | 0.30 | -0.17 | -0.18 | 0.09 |
| Diluted EPS | 0.05 | 0.30 | -0.17 | -0.18 | 0.09 |
| Basic average shares | 62.84M | 62.15M | 42.30M | 39.22M | 36.12M |
| Diluted average shares | 62.84M | 62.15M | 42.30M | 39.22M | 36.12M |
| EBITDA | 64.12M | 72.34M | 47.68M | 42.89M | 53.11M |
| Net income from continuing op. | 6.26M | 20.17M | -3.91M | -3.82M | 4.24M |
| Minority interests | -3.01M | -1.39M | -3.29M | -3.05M | -877,453 |
| Preferred stock dividends | — | — | — | — | — |
Balance sheet
| 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fiscal date | 2024-06-30 | 2023-06-30 | 2022-06-30 | 2021-06-30 | 2020-06-30 |
| Total assets | 850.63M | 818.06M | 518.22M | 394.59M | 297.56M |
| Current assets | |||||
| Cash | 44.47M | 48.13M | 32.91M | 28.33M | 20.18M |
| Cash equivalents | — | — | 562,380 | 7.72M | 22.35M |
| Cash and cash equivalents | 44.47M | 48.13M | 33.48M | 36.05M | 42.52M |
| Other short term investments | 11.70M | 11.92M | 5.14M | 10.74M | 9.05M |
| Accounts receivable | 207.32M | 158.01M | 111.75M | 88.78M | 73.55M |
| Other receivables | 2.83M | 1.86M | 2.39M | 103,974 | 207,168 |
| Inventory | 126.22M | 140.57M | 126.10M | 63.35M | 30.30M |
| Prepaid assets | 10.24M | 10.96M | 4.65M | 1.78M | 461,651 |
| Restricted cash | — | 212,703 | 265,123 | 425,976 | 4.39M |
| Assets held for sale | — | — | — | — | — |
| Hedging assets | — | — | — | — | — |
| Other current assets | — | — | — | — | — |
| Non current assets | |||||
| Properties | 60.66M | 57.31M | 52.80M | 42.81M | 35.81M |
| Land and improvements | — | — | — | — | — |
| Machinery furniture equipment | 22.61M | 19.80M | 27.72M | 20.49M | 18.56M |
| Construction in progress | 12.28M | 11.91M | 3.14M | 2.00M | 1.27M |
| Leases | — | — | — | — | — |
| Accumulated depreciation | -9.38M | -7.23M | -21.61M | -16.02M | -13.01M |
| Goodwill | 399.48M | 398.11M | 148.85M | 124.84M | 86.39M |
| Investment properties | 560,783 | 3.59M | — | — | — |
| Financial assets | — | — | — | — | — |
| Intangible assets | 174.80M | 173.78M | 76.70M | 67.34M | 35.33M |
| Investments and advances | 40.42M | 39.74M | 39.17M | 31.75M | 24.98M |
| Other non current assets | 42.93M | 9.65M | 6.51M | 5.97M | 4.40M |
| Total liabilities | 501.06M | 487.56M | 359.92M | 304.30M | 236.81M |
| Current liabilities | |||||
| Accounts payable | 161.93M | 146.26M | 124.41M | 69.25M | 53.76M |
| Accrued expenses | — | — | — | — | — |
| Short term debt | 139.87M | 111.50M | 72.71M | 77.54M | 64.39M |
| Deferred revenue | 3.92M | 24.88M | 5.90M | 6.28M | 2.87M |
| Tax payable | 10.47M | 4.07M | 8.80M | 10.01M | 3.72M |
| Pensions | 7.34M | 9.61M | 7.62M | 4.68M | 4.51M |
| Other current liabilities | 4.81M | 1.42M | 3.05M | — | — |
| Non current liabilities | |||||
| Long term debt | 131.08M | 145.91M | 97.07M | 97.04M | 84.70M |
| Provision for risks and charges | — | — | — | — | — |
| Deferred liabilities | 34.50M | 35.79M | 29.01M | 25.70M | 16.86M |
| Derivative product liabilities | — | — | — | — | 1.69M |
| Other non current liabilities | 2.50M | 3.58M | 9.85M | 11.79M | 452,654 |
| Shareholders equity | |||||
| Common stock | 6,500 | 6,493 | 4,637 | 4,158 | 3,613 |
| Retained earnings | -10.66M | -13.90M | -32.68M | -25.48M | -18.61M |
| Other shareholders equity | 633,487 | 1.12M | 1.98M | -27.37M | -35.80M |
| Total shareholders equity | 349.56M | 330.50M | 158.30M | 90.29M | 60.75M |
| Additional paid in capital | 326.86M | 326.25M | 157.90M | 119.75M | 96.49M |
| Treasury stock | 31.29M | 30.55M | 3.53M | 3.53M | 30,906 |
| Minority interest | 35.30M | 31.65M | 30.68M | 22.55M | 14.57M |
Cash flow statement
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | 6.26M | 20.17M | -3.91M | -3.82M | 4.24M | -16.36M | 742,351 | -14.31M |
| Depreciation | 21.30M | 19.39M | 9.19M | 6.26M | 4.73M | 4.83M | — | 4.37M |
| Deferred Taxes | 3.78M | -1.07M | 17.97M | 14.35M | 2.21M | 6.99M | — | -10.93M |
| Stock-Based Compensation | 14.13M | 3.42M | 1.43M | 1.66M | 3.43M | -102,827 | — | 30,005 |
| Other Non-Cash Items | 38.34M | 43.00M | 20.43M | 27.05M | 31.99M | 45.71M | — | 43.21M |
| Accounts Receivable | -51.65M | -68.34M | -32.27M | -6.34M | -26.61M | 47.26M | — | 17.83M |
| Accounts Payable | — | -4.50M | 53.48M | -5.83M | 8.27M | -33.70M | — | -35.29M |
| Other Assets & Liabilities | -4.10M | -12.26M | -82.06M | -47.52M | -21.67M | -23.30M | — | 9.44M |
| Operating Cash Flow | 28.06M | -192,302 | -15.74M | -14.20M | 6.59M | 31.33M | 742,351 | 14.35M |
| Investing Activities | ||||||||
| Capital Expenditures | -9.45M | -11.22M | -1.41M | -2.50M | -1.60M | -1.73M | — | -2.68M |
| Net Intangibles | -1.14M | -449,673 | -389,039 | -7.21M | -1.59M | -722,833 | — | -614,529 |
| Net Acquisitions | 37,508 | 4.37M | — | 253,921 | — | -129,340 | — | — |
| Purchase of Investments | -7.21M | -8.99M | -2.06M | -4.28M | -3.36M | — | -116.15M | — |
| Sale of Investments | 888,140 | 1.32M | 12.33M | 9.32M | 5,041 | — | — | — |
| Investing Cash Flow | -15.74M | -14.52M | 8.44M | 2.81M | -4.95M | -1.86M | -232.30M | -5.30M |
| Financing Activities | ||||||||
| Long-Term Debt Issuance | 135.82M | 79.82M | 140.43M | 143.50M | 135.35M | 88.69M | — | 27.75M |
| Long-Term Debt Payments | -117.49M | -20.60M | -111.69M | -117.27M | -101.75M | -111.08M | -200,000 | -37.62M |
| Other Financing Charges | -2.92M | -5.22M | -904,967 | -1.42M | 2.30M | 413,902 | 4.88M | -1.79M |
| Financing Cash Flow | 14.67M | 51.00M | 27.80M | 17.87M | 33.53M | -26.95M | 117.18M | -10.46M |
| Other Cash Details | ||||||||
| End Cash Position | 44.47M | 48.13M | 33.48M | 36.05M | 42.52M | 3.45M | 337,004 | 2.22M |
| Income Tax Paid | — | — | — | — | — | — | — | — |
| Interest Paid | — | — | — | — | — | — | — | — |
| Free Cash Flow | 18.93M | -19.97M | -26.51M | -20.13M | 4.82M | 26.25M | -1.00M | 12.68M |
Top Institutional Holders
| Holder | Date Reported | Shares | Value | % Held |
|---|---|---|---|---|
| Global X Fds-Global X MSCI Argentina ETF | Nov 30, 2024 | 587,582 | 3.92M | 0.94% |
| Unified Series Trust-Ballast Small/Mid Cap ETF | Sep 30, 2024 | 271,138 | 1.81M | 0.43% |
| Royce Smaller Companies Growth Fund | Sep 30, 2024 | 155,000 | 1.03M | 0.25% |
| Datum One Series Tr-Polar Capital Emerging Market Stars Fd | Sep 30, 2024 | 96,703 | 645,009 | 0.15% |
| Royce Micro Cap Trust | Sep 30, 2024 | 50,000 | 333,500 | 0.08% |
| Global Macro Capital Opportunities Portfolio | Oct 31, 2024 | 50,100 | 334,167 | 0.08% |
| Fidelity NASDAQ Composite Index Fund | Nov 30, 2024 | 38,927 | 259,643 | 0.06% |
| Royce Small Cap Trust, Inc. | Sep 30, 2024 | 24,147 | 161,060 | 0.04% |
| DFA U.S. Micro Cap Series | Oct 31, 2024 | 15,939 | 106,313 | 0.03% |
| DFA U.S. Small Cap Series | Oct 31, 2024 | 9,257 | 61,744 | 0.01% |
Article
Bioceres Crop Solutions Updates Second Fiscal Quarter 2025 Expectations
ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (NASDAQ: BIOX) today provided preliminary revenues, gross profit and adjusted EBITDA for the fiscal second quarter, ended December 31, 2024. Second quarter revenues are expected to be approximately $105 million, with gross profit of $45 million and adjusted EBITDA of $15 million. These results reflect challenging conditions in Argentina, which remains a decisive market for the financial performance of the company in the first ha.
Feb 6, 2025
Article
Bioceres Crop Solutions to Host Fiscal Second Quarter 2025 Financial Results Conference Call on Wednesday, February 12, 2025 at 8:30 a.m. Eastern Time
ROSARIO, Argentina--(BUSINESS WIRE)--Bioceres Crop Solutions Corp. (NASDAQ: BIOX) (“Bioceres” or the “Company”), a leader in the development and commercialization of productivity solutions designed to regenerate agricultural ecosystems while making crops more resilient to climate change, will hold a conference call on Wednesday, February 12, 2025 at 8:30 a.m. Eastern Time to discuss its results for the fiscal second quarter ended December 31, 2024. A press release detailing these results will b.
Jan 30, 2025
Article
Bioceres Is Getting Cheaper, Not Yet An Opportunity But More Interesting
Bioceres' 1Q25 results were challenging due to adverse weather in Argentina, affecting crop nutrition, protection, and seeds, but potential recovery is expected in 2Q25. BIOX has depreciated significantly, now trading at $6.7 per share, with a market cap of $400 million, making it a more interesting Hold. Despite some improvements, HB4 commercialization remains underwhelming, and financial risks persist, warranting caution before investing in potential developments.
Nov 13, 2024
